| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 40.305 | 53.953 | 26.128 | 20.154 | 22.317 | 10.858 | 38.015 | 59.910 | 21.840 | 54.606 |
| Total Income - EUR | 45.810 | 54.444 | 26.136 | 20.160 | 22.322 | 10.866 | 42.181 | 59.935 | 22.127 | 54.616 |
| Total Expenses - EUR | 56.568 | 49.787 | 31.797 | 30.266 | 21.602 | 11.382 | 28.529 | 24.568 | 17.155 | 27.193 |
| Gross Profit/Loss - EUR | -10.757 | 4.657 | -5.661 | -10.106 | 720 | -516 | 13.652 | 35.367 | 4.972 | 27.423 |
| Net Profit/Loss - EUR | -10.757 | 3.024 | -6.543 | -10.711 | 50 | -842 | 12.411 | 33.838 | 4.230 | 23.647 |
| Employees | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Oncorad Med Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 18.038 | 11.536 | 5.422 | 12 | 5 | 0 | 0 | 0 | 590 | 1.370 |
| Current Assets | 39.053 | 44.498 | 44.131 | 34.061 | 36.493 | 37.985 | 49.348 | 82.987 | 55.961 | 78.152 |
| Inventories | 25.834 | 25.570 | 25.138 | 24.676 | 27.646 | 27.122 | 23.213 | 23.285 | 23.215 | 23.085 |
| Receivables | 4.661 | 2.965 | 14.255 | 2.487 | 2.537 | 3.976 | 2.597 | 1.253 | 1.215 | 1.244 |
| Cash | 8.558 | 15.963 | 4.738 | 6.898 | 6.309 | 6.886 | 23.538 | 58.449 | 31.531 | 53.823 |
| Shareholders Funds | 13.123 | 16.013 | 9.199 | -1.680 | -1.598 | -2.410 | 10.055 | 43.925 | 24.568 | 48.077 |
| Social Capital | 112 | 111 | 109 | 107 | 105 | 103 | 101 | 101 | 101 | 101 |
| Debts | 45.199 | 40.424 | 40.445 | 35.754 | 38.096 | 40.394 | 39.293 | 39.063 | 31.983 | 31.445 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4773 - 4773" | |||||||||
| CAEN Financial Year |
4773
|
|||||||||
Comments - Oncorad Med Srl